4.2 Article

Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir

Journal

TRANSPLANT INFECTIOUS DISEASE
Volume 12, Issue 6, Pages 513-517

Publisher

WILEY
DOI: 10.1111/j.1399-3062.2010.00582.x

Keywords

peramivir; zanamivir; influenza; H275Y; resistance

Funding

  1. Adamas
  2. Glaxo-Smith-Kline
  3. Roche
  4. National Institutes of Health (NIH) [A-18029, CA-15704, K24HL093294, K23HL096831]
  5. ASBMT/Viropharma New Investigator Award

Ask authors/readers for more resources

P>Oseltamivir resistance in pandemic 2009 influenza A/H1N1 is caused by the neuraminidase mutation H275Y. This mutation has also been associated with in vitro resistance to peramivir, but few clinical cases have been described to date. Using allele-specific real-time reverse transcriptase polymerase chain reaction assay for the H275Y mutation, we were able to identify resistant H1N1 in a hematopoietic cell transplant recipient receiving intravenous peramivir therapy, and through serial testing we determined the molecular evolution of resistance. This case demonstrates that an H275Y mutant population can emerge early and replicate in vivo under peramivir antiviral pressure to become the major viral population.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biophysics

Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach

Masumi Ueda Oshima, Brenda M. Sandmaier, Effie Petersdorf, Mary E. Flowers, Geoffrey R. Hill, Stephanie J. Lee, Frederick R. Appelbaum, Paul A. Carpenter, K. Scott Baker, Laura Connelly-Smith, Andrea McCool, Suni Elgar, Steven A. Pergam, Catherine Liu, F. Marc Stewart, Marco Mielcarek

Summary: This article summarizes the experience gained by the Fred Hutchinson Cancer Research Center during the COVID-19 pandemic, focusing on the challenges faced and guiding principles for stem cell transplants in the pandemic setting. The article also discusses the potential impact of directing clinical resources towards COVID-19 care on cancer patients in need of stem cell transplantation.

BONE MARROW TRANSPLANTATION (2021)

Review Surgery

The limits of refusal: An ethical review of solid organ transplantation and vaccine hesitancy

Olivia S. Kates, Erica J. Stohs, Steven A. Pergam, Robert M. Rakita, Marian G. Michaels, Cameron R. Wolfe, Lara Danziger-Isakov, Michael G. Ison, Emily A. Blumberg, Raymund R. Razonable, Elisa J. Gordon, Douglas S. Diekema

Summary: Patients undergoing solid organ transplantation should receive multiple vaccines to prevent diseases, but increasing vaccine refusal poses challenges for transplant centers. A uniform national policy addressing vaccine refusal among transplant candidates is needed to establish a consistent approach.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Article Immunology

Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance

Julian Lindsay, Jad Othman, Ian Kerridge, Keith Fay, William Stevenson, Chris Arthur, Sharon C-A Chen, David C. M. Kong, Steven A. Pergam, Catherine Liu, Monica A. Slavin, Matthew Greenwood

Summary: CMV reactivation is common after alloHCT, especially in D-/R+ URD recipients. This study suggests that cs-CMVi is associated with increased non-relapse mortality and that initiating preemptive therapy beyond a viral load of 250 IU/mL may be beneficial in preventing CMV-related complications.

TRANSPLANT INFECTIOUS DISEASE (2021)

Article Medicine, General & Internal

Assessment of the Inclusion of Racial/Ethnic Minority, Female, and Older Individuals in Vaccine Clinical Trials

Laura E. Flores, Walter R. Frontera, Michele P. Andrasik, Carlos Del Rio, Antonio Mondriguez-Gonzalez, Stephanie A. Price, Elizabeth M. Krantz, Steven A. Pergam, Julie K. Silver

Summary: This study found that members of racial/ethnic minority groups and older adults were underrepresented in US-based vaccine clinical trials, while female adults were overrepresented. It is recommended that diversity enrollment targets be included in all vaccine trials targeting epidemiologically important infections.

JAMA NETWORK OPEN (2021)

Article Oncology

Cocooning Against COVID-19: The Argument for Vaccinating Caregivers of Patients With Cancer

Maresa C. Woodfield, Steven A. Pergam, Parth D. Shah

Summary: It is suggested that cocoon vaccination strategies should be used to protect cancer patients in the COVID-19 vaccination race. Medical systems specializing in cancer care should support education and vaccination campaigns targeting informal caregivers and household contacts, in addition to cancer patients.

CANCER (2021)

Letter Oncology

Care without a compass: Including patients with cancer in COVID-19 studies

Christopher R. Friese, Toni K. Choueiri, Narjust Duma, Dimitrios Farmakiotis, Petros Grivas, Brian I. Rini, Dimpy P. Shah, Michael A. Thompson, Steven A. Pergam, Sanjay Mishra, Jeremy L. Warner

CANCER CELL (2021)

Editorial Material Immunology

Can a Simple Stool Swab Predict Bacteremia in High-Risk Hematopoietic Cell Transplant Recipients?

Steven A. Pergam, Sanjeet S. Dadwal

CLINICAL INFECTIOUS DISEASES (2021)

Editorial Material Immunology

Behind the Scenes Heroes: The COVID-19 Vaccine Data and Safety Monitoring Board COMMENT

Lawrence Corey

JOURNAL OF INFECTIOUS DISEASES (2021)

Article Medicine, General & Internal

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

L. Corey, P. B. Gilbert, M. Juraska, D. C. Montefiori, L. Morris, S. T. Karuna, S. Edupuganti, N. M. Mgodi, A. C. deCamp, E. Rudnicki, Y. Huang, P. Gonzales, R. Cabello, C. Orrell, J. R. Lama, F. Laher, E. M. Lazarus, J. Sanchez, I. Frank, J. Hinojosa, M. E. Sobieszczyk, K. E. Marshall, P. G. Mukwekwerere, J. Makhema, L. R. Baden, J. I. Mullins, C. Williamson, J. Hural, M. J. McElrath, C. Bentley, S. Takuva, M. M. Gomez Lorenzo, D. N. Burns, N. Espy, A. K. Randhawa, N. Kochar, E. Piwowar-Manning, D. J. Donnell, N. Sista, P. Andrew, J. G. Kublin, G. Gray, J. E. Ledgerwood, J. R. Mascola, M. S. Cohen

Summary: The study found that broadly neutralizing antibodies did not prevent HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates indicated that prophylaxis with broadly neutralizing antibodies may be effective.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Letter Immunology

SARS-CoV-2 Vaccination and Solid Organ Transplant Patients: Data Needed to Inform Safety and Efficacy

Michael G. Ison, Robin Avery, Emily Blumberg, Peter Chin-Hong, Natasha Halasa, Dan Kaul, Steve Pergam, Nicole M. Theodoropoulos, Cameron R. Wolfe

TRANSPLANTATION (2021)

Article Medicine, General & Internal

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

Dean Follmann, Holly E. Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen Kotloff, Michael Desjardins, Lawrence Corey, Kathleen M. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden

Summary: This study evaluated the seropositivity of anti-nucleocapsid antibody (anti-N Ab) in mRNA-1273 vaccinees with breakthrough SARS-CoV-2 infection. The results showed a lower seroconversion rate in vaccinees, indicating the importance of considering vaccination status when interpreting seroprevalence and seropositivity data based solely on anti-N Ab testing.

ANNALS OF INTERNAL MEDICINE (2022)

Review Immunology

KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine

Corey Casper, Lawrence Corey, Jeffrey Cohen, Blossom Damania, Anne A. Gershon, David C. Kaslow, Laurie T. Krug, Jeffrey Martin, Sam M. Mbulaiteye, Edward S. Mocarski, Patrick S. Moore, Javier Gordon Ogembo, Warren Phipps, Denise Whitby, Charles Wood

Summary: This article summarizes the epidemiology and biology of Kaposi sarcoma herpesvirus (KSHV) as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.

NPJ VACCINES (2022)

Article Medicine, Research & Experimental

Novel engineered chimeric engulfment receptors trigger T cell effector functions against SIV-infected CD4+T cells

Daniel Corey, Francoise Haeseleer, Joe Hou, Lawrence Corey

Summary: Adoptive therapy using genetically engineered T cells shows promise in treating infectious diseases in immunocompromised individuals. In this study, chimeric engulfment receptor (CER) T cells designed to recognize phosphatidylserine (PS)-expressing cells successfully eliminated SIV-infected cells. The introduction of innate immune functions into T cells enhances the elimination of SIV-infected cells, and further in vivo studies are needed to evaluate their effectiveness.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2023)

Article Immunology

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women

Deborah Donnell, Fei Gao, James P. Hughes, Brett Hanscom, Lawrence Corey, Myron S. Cohen, Srilatha Edupuganti, Nyaradzo Mgodi, Helen Rees, Jared M. Baeten, Glenda Gray, Linda-Gail Bekker, Mina Hosseinipour, Sinead Delany-Moretlwe

Summary: This study used counterfactual placebo comparisons using other data sources to evaluate the efficacy of antiretroviral agents for HIV pre-exposure prophylaxis. The findings showed that injectable cabotegravir (CAB-LA) and daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can significantly reduce the risk of HIV infection compared to no intervention, and the efficacy of FTC/TDF against counterfactual placebo was consistent with previous placebo-controlled trials.

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2023)

Article Medicine, Research & Experimental

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Magdalena E. Sobieszczyk, Jill Maaske, Ann R. Falsey, Stephanie Sproule, Merlin L. Robb, Robert W. Frenck, Hong-Van Tieu, Kenneth H. Mayer, Lawrence Corey, Kathleen M. Neuzil, Tina Tong, Margaret Brewinski Isaacs, Holly Janes, Himanshu Bansal, Lindsay M. Edwards, Justin A. Green, Elizabeth J. Kelly, Kathryn Shoemaker, Therese Takas, Tom White, Prakash Bhuyan, Tonya Villafana, Ian Hirsch

Summary: AZD1222 vaccine demonstrated safety, efficacy, and immunogenicity in the ongoing phase 3 trial. The vaccine provided durable protection with a significant reduction in the incidence of symptomatic COVID-19 and showed high efficacy against severe/critical disease. Humoral immune responses induced by AZD1222 waned over time.

JOURNAL OF CLINICAL INVESTIGATION (2022)

No Data Available